FHIR-45328 |
Tag bundles to identify which use case is being reported |
FHIR-45327 |
Support Catchment Area |
FHIR-44524 |
Revise Introduction to include other approaches than MedMorph RA |
FHIR-44516 |
Clarify sections included in profile content table and not in the Intro section |
FHIR-44513 |
Revise workflow to incorporate De-Identification and use UDS+ approach |
FHIR-44025 |
Clarify scope of catchment area |
FHIR-44024 |
Clarify scope to include test RESULTS available in hospital system |
FHIR-43823 |
Fix Update Capability Statement description |
FHIR-43680 |
Data for the disease burden project are not anonymous to the RESP-NET site |
FHIR-43679 |
Consider adding a hospital identifier |
FHIR-43678 |
Section’s title should be changed for consistent terminology throughout |
FHIR-43677 |
Can the system distinguish between patient discharge vs. patient transfer to another hospital? |
FHIR-43676 |
Restate description for Use Cases 4 and 5 |
FHIR-43675 |
Evaluate the consistency of using “case” |
FHIR-43604 |
References to MedMorph create ambiguity |
FHIR-43598 |
Subscription requirement |
FHIR-43584 |
Focus IG on Knowledge and Content |
FHIR-43534 |
Data Element Requirements |
FHIR-43532 |
Editorial Updates in 7.1.1 CapabilityStatement |
FHIR-43503 |
Clarify the Pregnancy Outcome entry |
FHIR-43502 |
Content missing from the Composition profile narrative |
FHIR-43500 |
Clarify placement of DiagnosticReport in the Composition |
FHIR-43498 |
Possible duplicate entry in Composition narrative |
FHIR-43497 |
Clarify use of MedicationReference slice |
FHIR-43496 |
Clarify usage of Medication resources in Composition profile |
FHIR-43495 |
Clarify the nature of requirements in the Composition profile narrative |
FHIR-43493 |
Please confirm the use of the Composition.type LOINC code |
FHIR-43492 |
Clarify the 72 hours threshold after encounter close |
FHIR-43491 |
Missing word in Section 3.4.5 |
FHIR-43490 |
Figure text overlaps a line |
FHIR-43489 |
Inconsistency in COVID references |
FHIR-43486 |
Clarify reporting requirement time frame |
FHIR-43485 |
Alignment of Use Cases 1,2 and 3 |
FHIR-43462 |
Clarify monitoring of positive patients |
FHIR-43461 |
Remove references to BSA |